pHOXBIO announced results from a randomized, double-blind, placebo-controlled clinical trial showing that pHOXWELL, its prophylactic nasal spray, prevented infection from SARS-CoV-2, the virus that causes COVID-19.
In a Phase 2/3 clinical study, there were 63% fewer SARS-CoV-2 infections in high-risk healthcare workers given pHOXWELL compared to placebo.
pHOXWELL is a self-administered prophylactic nasal spray designed to offer a variant-agnostic mechanism of action that inhibits the infection processes of SARS-CoV-2. It is designed to be effective against other airborne respiratory viruses. The product offers 6-8 hours of protection with just two sprays per nostril, per application.
The study was a double-blind, randomized, placebo-controlled study to assess the efficacy and safety of the pHOXWELL nasal spray in the prevention of SARS-CoV-2 infection in high-risk healthcare professionals in India. The trial was carried out during the peak surge of the highly infectious Delta variant in India from April to July 2021.
